Abstract 458P
Background
Venous Thromboembolism (VTE) is a common cardiovascular disease affecting cancer patient with related poor prognosis and short survival. Different scoring systems and certain genetic polymorphisms were used to predict patient's risk for VTE. This study aimed to investigate the association between TSPAN15 (rs78707713) and SLC44A2 (rs2288904) genetic polymorphisms and VTE in cancer patients in correlation with PROTECHT scoring system and survival.
Methods
This case control study was carried out on 100 cancer patients, group I included 50 consecutive cancer patients with VTE, and group II included 50 selected cancer patients without VTE with age and cancer diagnosis matched to group I as a control. Full history taking and clinical examination and all clinical data were recorded. Laboratory investigations including CBC, coagulation profile and analysis of TSPAN15 (rs78707713) and SLC44A2 (rs2288904) SNPs by PCR were assessed. Radiological imaging of VTE by duplex ultrasound, CT pulmonary angiography were done according to the clinical scenario. PROTECHT score and survival analysis were calculated.
Results
Cancer patients with VTE had high tumor grade, increased incidence of metastasis with shorter progression free survival (PFS) compared with cancer patients without VTE. Partial immobilization and hospitalization were significantly associated with the occurrence of VTE in cancer patients. Regarding cancer treatment, the use of gemcitabine-based chemotherapy was associated with an increased risk for VTE. The most frequent SLC44A2 (rs2288904) genotype was GG followed by AG in cancer patients with VTE. Whereas GG and AG genotypes were equally distributed in cancer patients without VTE, The GG genotype had high risk PROTECHT score compared with AA and AG genotypes. The commonest TSPAN15 (rs78707713) genotypes were TC and CC in cancer patients with VTE versus TC and TT in cancer patients without VTE. The CC genotype had high PROTECHT score points compared with TC and TT genotypes. Furthermore, TC and CC cancer patients with VTE had significantly high tumor grade.
Conclusions
Screening of SLC44A2 (rs2288904) and TSPAN15 (rs78707713) genetic variants may enhance the ability to predict VTE risk in cancer patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Menoufeya University.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
551P - Real-world incidence and outcomes of immune-related adverse events in NSCLC patients
Presenter: Andrea Knox
Session: Poster Display
Resources:
Abstract
552P - TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in Asian patients (pts) with previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs)
Presenter: Yasushi Goto
Session: Poster Display
Resources:
Abstract
553P - Preceding plasma EGFR vs upfront tissue NGS for advanced NSCLC in the Chinese population: A single centre experience in Hong Kong
Presenter: Janet Du
Session: Poster Display
Resources:
Abstract
554P - Comparison of the analytical performance of endobronchial ultrasound-guided transbronchial needle aspiration and other sampling methods for the Oncomine Dx target test: An observational study
Presenter: Kazuhito Miyazaki
Session: Poster Display
Resources:
Abstract
555P - Quality of life in patients with stage IV non-small cell lung cancer and the influence of druggable mutations over time: A prospective, territory-wide study in Hong Kong
Presenter: Jason C S Ho
Session: Poster Display
Resources:
Abstract
556P - Results from the phase I study on efficacy and safety of iruplinalkib (WX-0593) for anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) patients who received prior second-generation ALK tyrosine kinase inhibitors (TKIs)
Presenter: xuezhi Hao
Session: Poster Display
Resources:
Abstract
557P - Longitudinal plasma proteomic profiling of EML4-ALK positive lung cancer receiving ALK-TKIs therapy
Presenter: Shasha Wang
Session: Poster Display
Resources:
Abstract
558P - Treatment duration and adherence of brigatinib as second-line treatment after crizotinib for ALK+ NSCLC in South Korea
Presenter: Jeong Eun Lee
Session: Poster Display
Resources:
Abstract
559P - Comprehensive survey of AACR GENIE database revealed a wide range of TMB distribution among all three classes (I, II, III) of BRAF mutated NSCLC
Presenter: Zhaohui Arter
Session: Poster Display
Resources:
Abstract
560P - Triple-targeted therapy of dabrafenib, trametinib and osimertinib for the treatment of acquired BRAF V600E mutation after progression on EGFR-TKIs in advanced EGFR-mutant NSCLC
Presenter: Chengdi Weng
Session: Poster Display
Resources:
Abstract